Related references
Note: Only part of the references are listed.Determining generalizability of he Canadian Kidney Cancer information system (CKCis) to the entire Canadian kidney cancer population
Camilla Tajzler et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2020)
Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience
Alice Dragomir et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2020)
Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma
Ciro Franzese et al.
JOURNAL OF UROLOGY (2019)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma
Daniel Reinhorn et al.
ONCOLOGIST (2019)
Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China
Jun Chen et al.
CLINICAL DRUG INVESTIGATION (2019)
Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019
Sebastien J. Hotte et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2019)
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial
Axel Bex et al.
JAMA ONCOLOGY (2019)
Cytoreductive nephrectomy in the current treatment algorithm
Teele Kuusk et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review
Idir Ouzaid et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
A. Mejean et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma
Davide Bimbatti et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Comparison of stereotactic body radiotherapy versus metastasectomy outcomes in patients with pulmonary metastases
Yun Hee Lee et al.
THORACIC CANCER (2018)
Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases
Chiachien Jake Wang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Brian I. Rini et al.
LANCET ONCOLOGY (2016)
Deferred Systemic Therapy in Patients With Metastatic Renal Cell Carcinoma
Aaron P. Mitchell et al.
CLINICAL GENITOURINARY CANCER (2015)
Active surveillance for metastatic or recurrent renal cell carcinoma
Inkeun Park et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
First Experience of Active Surveillance Before Systemic Target Therapy in Patients With Metastatic Renal Cell Carcinoma
Nobuaki Matsubara et al.
UROLOGY (2013)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
RC Flanigan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
GHJ Mickisch et al.
LANCET (2001)
Share Paper
